Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma
In the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entitie...
| Autores: | , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2019 |
| País: | España |
| Recursos: | Universitat Autònoma de Barcelona |
| Repositorio: | Dipòsit Digital de Documents de la UAB |
| Idioma: | inglés |
| OAI Identifier: | oai:ddd.uab.cat:223420 |
| Acesso em linha: | https://ddd.uab.cat/record/223420 https://dx.doi.org/urn:doi:10.3389/fgene.2019.00986 |
| Access Level: | acceso abierto |
| Palavra-chave: | B-cell lymphoma DNMT EZH2 HDAC PRMT inhibitor BET bromodomain inhibitor (BETi) Combination therapy |
| id |
ES_85b5fb31369b52b2a02ba345c1aef4fe |
|---|---|
| oai_identifier_str |
oai:ddd.uab.cat:223420 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphomaRibeiro, Marcelo L.|||0000-0003-4529-7832Reyes Garau, Diana|||0000-0002-6124-8953Armengol, Marc Antoni|||0000-0001-5206-9139Roué, Gaël|||0000-0003-0245-2257B-cell lymphomaDNMTEZH2HDACPRMT inhibitorBET bromodomain inhibitor (BETi)Combination therapyIn the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entities remain incurable and current treatments are associated with variable efficacy, several adverse events, and frequent relapses. Thus, new diagnostic paradigms and novel therapeutic options are required to improve the prognosis of patients with B-NHL. With the recent deciphering of the mutational landscapes of B-cell disorders by high-throughput sequencing, it came out that different epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the clinical management of B-NHL patients. In this review, we will present an overview of the most relevant epidrugs tested and/or used so far for the treatment of different subtypes of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases (HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity for proteins that are mutated, translocated, and/or overexpressed in these diseases, including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy in refractory patients. This review will also provide a summary of the latest strategies being employed in preclinical and clinical settings, and will point out the most promising lines of investigation in the field.Universitat Autònoma de Barcelona 22019-01-0120192019-01-01Article de revisióhttp://purl.org/coar/resource_type/c_dcae04bcVoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/223420https://dx.doi.org/urn:doi:10.3389/fgene.2019.00986reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengInstituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18-01383Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI15-00102open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2234202026-06-06T12:50:31Z |
| dc.title.none.fl_str_mv |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma |
| title |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma |
| spellingShingle |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma Ribeiro, Marcelo L.|||0000-0003-4529-7832 B-cell lymphoma DNMT EZH2 HDAC PRMT inhibitor BET bromodomain inhibitor (BETi) Combination therapy |
| title_short |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma |
| title_full |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma |
| title_fullStr |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma |
| title_full_unstemmed |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma |
| title_sort |
Recent advances in the targeting of epigenetic regulators in b-cell non-hodgkin lymphoma |
| dc.creator.none.fl_str_mv |
Ribeiro, Marcelo L.|||0000-0003-4529-7832 Reyes Garau, Diana|||0000-0002-6124-8953 Armengol, Marc Antoni|||0000-0001-5206-9139 Roué, Gaël|||0000-0003-0245-2257 |
| author |
Ribeiro, Marcelo L.|||0000-0003-4529-7832 |
| author_facet |
Ribeiro, Marcelo L.|||0000-0003-4529-7832 Reyes Garau, Diana|||0000-0002-6124-8953 Armengol, Marc Antoni|||0000-0001-5206-9139 Roué, Gaël|||0000-0003-0245-2257 |
| author_role |
author |
| author2 |
Reyes Garau, Diana|||0000-0002-6124-8953 Armengol, Marc Antoni|||0000-0001-5206-9139 Roué, Gaël|||0000-0003-0245-2257 |
| author2_role |
author author author |
| dc.contributor.none.fl_str_mv |
Universitat Autònoma de Barcelona |
| dc.subject.none.fl_str_mv |
B-cell lymphoma DNMT EZH2 HDAC PRMT inhibitor BET bromodomain inhibitor (BETi) Combination therapy |
| topic |
B-cell lymphoma DNMT EZH2 HDAC PRMT inhibitor BET bromodomain inhibitor (BETi) Combination therapy |
| description |
In the last 10 years, major advances have been made in the diagnosis and development of selective therapies for several blood cancers, including B-cell non-Hodgkin lymphoma (B-NHL), a heterogeneous group of malignancies arising from the mature B lymphocyte compartment. However, most of these entities remain incurable and current treatments are associated with variable efficacy, several adverse events, and frequent relapses. Thus, new diagnostic paradigms and novel therapeutic options are required to improve the prognosis of patients with B-NHL. With the recent deciphering of the mutational landscapes of B-cell disorders by high-throughput sequencing, it came out that different epigenetic deregulations might drive and/or promote B lymphomagenesis. Consistently, over the last decade, numerous epigenetic drugs (or epidrugs) have emerged in the clinical management of B-NHL patients. In this review, we will present an overview of the most relevant epidrugs tested and/or used so far for the treatment of different subtypes of B-NHL, from first-generation epigenetic therapies like histone acetyl transferases (HDACs) or DNA-methyl transferases (DNMTs) inhibitors to new agents showing selectivity for proteins that are mutated, translocated, and/or overexpressed in these diseases, including EZH2, BET, and PRMT. We will dissect the mechanisms of action of these epigenetic inhibitors, as well as the molecular processes underlying their lack of efficacy in refractory patients. This review will also provide a summary of the latest strategies being employed in preclinical and clinical settings, and will point out the most promising lines of investigation in the field. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2 2019-01-01 2019 2019-01-01 |
| dc.type.none.fl_str_mv |
Article de revisió http://purl.org/coar/resource_type/c_dcae04bc VoR http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.openaire.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| dc.identifier.none.fl_str_mv |
https://ddd.uab.cat/record/223420 https://dx.doi.org/urn:doi:10.3389/fgene.2019.00986 |
| url |
https://ddd.uab.cat/record/223420 https://dx.doi.org/urn:doi:10.3389/fgene.2019.00986 |
| dc.language.none.fl_str_mv |
Inglés eng |
| language_invalid_str_mv |
Inglés |
| language |
eng |
| dc.relation.none.fl_str_mv |
Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI18-01383 Instituto de Salud Carlos III https://doi.org/10.13039/501100004587 PI15-00102 |
| dc.rights.none.fl_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.openaire.fl_str_mv |
info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.source.none.fl_str_mv |
reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona |
| instname_str |
Universitat Autònoma de Barcelona |
| reponame_str |
Dipòsit Digital de Documents de la UAB |
| collection |
Dipòsit Digital de Documents de la UAB |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869412320383336448 |
| score |
15.811543 |